Aptamer Proteomics of Cardiometabolic and Renal Traits in African Americans
Aptamer Proteomics of Cardiometabolic and Renal Traits in African Americans
批准号:
9463647
负责人:
ROBERT E GERSZTEN
金额:
$144.29万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2021-02-28
关键词:
APOL1 geneAblationAddressAfrican AmericanAlcoholsAntibodiesAvidityBindingBioinformaticsBiological AssayBiological MarkersCardiacCardiovascular DiseasesChemicalsChronic Kidney FailureClinicalCohort StudiesCollaborationsCommunitiesComplementCoronary heart diseaseCross-Sectional StudiesCytokine ReceptorsDNADataDevelopmentDiabetes MellitusDiseaseDisease PathwayEarly treatmentEmerging TechnologiesEpidemiologyEthnic groupEuropeanEventFluorescenceFollow-Up StudiesFundingGeneticGenetic DeterminismGenotypeGlomerular Filtration RateHeart failureHigh Density Lipoprotein CholesterolHormone AntagonistsHumanHypertrophic CardiomyopathyIndividualInflammatoryInjuryInstitutesInterventionJackson Heart StudyKidneyKidney DiseasesKnowledgeLaboratoriesLeadLipoprotein (a)LipoproteinsMass Spectrum AnalysisMeasuresMedicineMeta-AnalysisMetabolic DiseasesMethodsMyocardialMyocardial InfarctionNon-Insulin-Dependent Diabetes MellitusOutcomePathogenesisPathogenicityPathway interactionsPatientsPatternPhenotypePlasmaPlasma ProteinsPopulationProtease InhibitorProtein ArrayProtein Array AnalysisProteinsProteomicsPublicationsReaderReproducibilityResearchResourcesRiskRisk FactorsRisk MarkerSamplingSickle Cell TraitSingle-Stranded DNASmokingSpecificityStrokeTechniquesTechnologyTestingTriglyceridesTroponinUniversitiesValidationVariantWorkaptamerbasecandidate markercardiometabolismcohortcoronary artery calciumdata acquisitiondatabase of Genotypes and Phenotypesdisorder riskexomefollow-upgenetic variantgenome wide association studyhealth disparityheart disease riskinsightliquid chromatography mass spectrometrymetabolomicsmultidisciplinarynovelnovel markernovel strategiesoffspringphenotypic datarisk varianttraitwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
There is a disproportionate burden of cardiometabolic disease and chronic kidney disease (CKD) among
African Americans (AA), but the responsible environmental and/or genetic mechanisms are incompletely
defined. Quantitation of selected plasma proteins is clinically valuable, and new findings presented here argue
strongly that broadening the array of proteins analyzed can provide new insight into pathogenesis and offer
novel markers of disease risk and events. To address important knowledge gaps, we propose to analyze an
unprecedented array of proteins in plasma samples of AA in the Jackson Heart Study (JHS) and the Southern
Community Cohort Study (SCCS). We will test the overall hypothesis that proteomic profiling in well-
phenotyped cohorts will identify new pathogenic pathways of particular importance in AA.
In Specific Aim 1, we propose cross-sectional studies to identify novel proteomic biomarkers of cardiometabolic
and renal traits. In Specific Aim 2, we will assess whether baseline plasma protein concentrations predict
incident coronary heart disease (CHD) and CKD. For Specific Aims 1 and 2 the JHS will be the discovery
cohort; cross-sectional and longitudinal findings will be clinically validated in the SCCS. In Specific Aim 3, we
will use GWAS, exome sequence, and whole genome sequence to explore the genetic determinants of
proteins that are associated with cardiometabolic disease and CKD, and will test whether variants that are
associated with protein levels predict incident CHD and CKD in large meta-analyses.
We will leverage a powerful new analytic platform in which single-stranded DNA molecules called aptamers
have been modified to have high avidity and specificity for an array of 1,310 targeted plasma proteins. The
aptamers bind in proportion to each protein's concentration, and are released and quantified by fluorescence,
using microarrays. We present extensive experimental validation of these analyses including orthogonal
validation by liquid chromatography-mass spectrometry. Our multi-disciplinary team at the JHS, BIDMC, Broad
Institute, and Vanderbilt University brings expertise in proteomics, biomarkers, genetic and population
epidemiology, bioinformatics, and health disparities. All data will be made publically available, providing a
unique and valuable resource to the scientific community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
-
批准号:10547825
-
项目类别:
-
资助金额:$51.49万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
A Multi-Dimensional Linked Registry to Identify Biological, Clinical, Health System, and Socioeconomic Risk Factors for COVID-19-Related Cardiovascular Events
-
批准号:10183512
-
项目类别:
-
资助金额:$87.32万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
A Multi-Dimensional Linked Registry to Identify Biological, Clinical, Health System, and Socioeconomic Risk Factors for COVID-19-Related Cardiovascular Events
-
批准号:10376347
-
项目类别:
-
资助金额:$87.09万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
-
批准号:10096791
-
项目类别:
-
资助金额:$58.35万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
A Multi-Dimensional Linked Registry to Identify Biological, Clinical, Health System, and Socioeconomic Risk Factors for COVID-19-Related Cardiovascular Events
-
批准号:10599322
-
项目类别:
-
资助金额:$86.58万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolite profiles and the risk of diabetes in Asians
-
批准号:10227610
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
-
批准号:10363615
-
项目类别:
-
资助金额:$57.44万
-
财政年份:2021
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham Study
-
批准号:9763974
-
项目类别:
-
资助金额:$273.01万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Plasma proteomics in CHS and population biology
-
批准号:9815869
-
项目类别:
-
资助金额:$179.99万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolic Phenotyping and Pharmocokinetics Core
-
批准号:10426365
-
项目类别:
-
资助金额:$58.05万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolic Phenotyping and Pharmocokinetics Core
-
批准号:9981039
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Plasma proteomics in CHS and population biology
-
批准号:9976578
-
项目类别:
-
资助金额:$208.34万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Plasma proteomics in CHS and population biology
-
批准号:10188618
-
项目类别:
-
资助金额:$107.61万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolic Phenotyping and Pharmocokinetics Core
-
批准号:10671662
-
项目类别:
-
资助金额:$38.51万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolic Phenotyping and Pharmocokinetics Core
-
批准号:10241496
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham Study
-
批准号:10754180
-
项目类别:
-
资助金额:$146.93万
-
财政年份:2019
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolite profiles and the risk of diabetes in Asians
-
批准号:9273192
-
项目类别:
-
资助金额:$66.98万
-
财政年份:2016
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Proteomic Pathway Discovery in Cardiovascular Disease
-
批准号:9301638
-
项目类别:
-
资助金额:$85.28万
-
财政年份:2016
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolomic phenotyping ("Metabolomics")
-
批准号:8411688
-
项目类别:
-
资助金额:$81.98万
-
财政年份:2012
-
负责人:ROBERT E GERSZTEN
-
依托单位:
Metabolomic Biomarkers of Early Myocardial Injury
-
批准号:7764455
-
项目类别:
-
资助金额:$80.54万
-
财政年份:2010
-
负责人:ROBERT E GERSZTEN
-
依托单位:
海外基金